Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.

This single arm, non-randomized, phase I/II study evaluated MEK162—an oral, selective small molecule inhibitor of MEK1/2&mdash;twice daily for 21 days with gemcitabine and cisplatin infusions on days 8 and 15.

This was based on preclinical data that showed that a certain cycling between gemcitabine, cisplatin, and the MEK inhibitor may allow the MEK to target the cells at their prime, says Abou-Alfa.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Abou-Alfa on Trial of MEK162 in Advanced Biliary Cancer